Updated GDP Guide for Excipients

In October 2024, the IPEC (International Pharmaceutical Excipients Council Europe (IPEC Europe) asbl) announced on its website the new version 3 of its GDP guide 'Good Distribution Practices Guide for Pharmaceutical Excipients'. The document is currently only available in the IPEC member area. The updated guide is to be published after a period of three months (probably at the beginning of 2025). It can be assumed that this will be available as usual under the 'Resources' section in the 'Guidelines' area of the IPEC website. You can currently view a summary and table of contents of the revised guide.

The table of contents of the new version is as follows:

1 INTRODUCTION
   1.1 Purpose
   1.2 Scope 
   1.3 Principles Adopted
2 PHARMACEUTICAL GRADE EXCIPIENTS
3 GOOD DISTRIBUTION ACTIVIES FOR PHARMACEUTICAL EXCIPIENTS
Table 1 Matrix of Applicability
Table 2 Applicability for Supply Chain Activities 
   1. Quality Management
   2. Organisation and personnel
   3. Premises
   4. Procurement, warehousing and storage
   5. Equipment
   6. Documentation
   7. Repackaging and relabelling
   8. Complaints
   9. Recalls
  10. Returned Goods
  11. Handling of non-conforming materials
  12. Dispatch and Transport
  13. Contract activities
4 REFERENCES

This largely corresponds to the table of content of the previous version from 2017, although subsections 1.1-1.3 have been added.

Comments

Post a Comment

Popular posts from this blog

FDA describes detailed CAPA Procedure in Warning Letter

An FDA Warning Letter is a formal communication from the US Food and Drug Administration (FDA) notifying a company or individual of regulatory violations. These typically describe observations made during an inspection and list violations found (referencing the specific sections of the FD&C Act, the Code of Federal Regulations (CFR), and other applicable laws as appropriate). In addition, specific measures are listed that the recipient must take to remedy the violations. It does not go into great detail, especially not with regard to instructions on the desired procedure. In a Warning Letter issued to Sun Pharmaceutical Industries Limited (India) at the beginning of July, this is now different. It describes in great detail what the FDA considers to be appropriate CAPA measures in a specific case. What happened? The company was criticised for not adequately cleaning and maintaining the equipment used to manufacture drug products. According to the company's response, a defective ...
Read more

FDA Warning Letter Missing Ongoing Stability Studies for APIs

Company Antaria Pty. Ltd, Australia Synopsis  1.Inadequate Investigation  2. Own Analytal Methods used but proved to equivalent to USP methods 3.Annual Stability missed 1.Failure to adequately investigate and document out-of-specification results and implement appropriate corrective actions . Your firm manufactures API (b)(4) USP, labeled in part to be the active ingredient used in (b)(4). You failed to adequately investigate out-of-specification (OOS) test results. Specifically, your firm lacked adequate investigations and corrective actions for numerous OOS results obtained during laboratory testing of your API, including assay and loss on ignition (LOI) testing. The root causes were not clearly defined nor adequately documented, and lots with OOS results were released by your quality unit (QU). In your response, you state that staff turnover and insufficient staff training attributes to the lack of competency in good laboratory practices . Additionally, you state that you...
Read more

Understand ICH Q7

What is meant by ‘quality unit(s) independent from production The intent of the term ‘independent’ is to prevent any conflict of interest and ensure unbiased decision-making regarding quality-related decisions in the organization structure. The person in the quality unit who is responsible for final decision-making (e.g., batch release decision) should not have responsibilities for production activities [ICH Q7, 2.13]. Does ICH Q7 expect that the quality unit performs API release testing While the quality unit has responsibility for the release of the API, which includes oversight of the testing and results, ICH Q7 does not prescribe specifically who performs testing. ‘Quality control’ in the ICH Q7 Glossary [ICH Q7, 20] refers to the activities, not the organisational structure. For examples of quality responsibility related to testing and release, refer to [ICH Q7, 2.13, 2.22, and 11.12]. Appropriate laboratory controls should be followed [ICH Q7, 11.10, 16.10] regardless of who ...
Read more